Marksans Pharma Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2025.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma has filed its unaudited financial results for the quarter and half year ended September 30, 2025 with the stock exchange. The filing covers both the standalone Q2 (July–September 2025) and the first half of FY26 performance. Detailed line items such as revenue, operating profit, and net profit are not visible from the headline alone. Investors will need to look at the full results document for specific numbers and segment performance. This is a routine regulatory filing required of all listed companies within 45 days of quarter-end.
Neutral to mildly informative — the filing itself is procedural, but the underlying numbers (once reviewed) could move the stock depending on whether revenue, margins, and profits beat or miss street expectations.